

Intermittent rehabilitation in the therapy of type 2 diabetes

Submission date
10/08/2006

Recruitment status
No longer recruiting

☐ Prospectively registered

☐ Protocol

Registration date
04/12/2006

Overall study status
Completed

☐ Statistical analysis plan

☒ Results

Last Edited
06/01/2021

Condition category
Nutritional, Metabolic, Endocrine

☐ Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Peter Hübner

Contact details
Hochstrasse 13-19
Bad Neuenahr
Germany
53474
+49 (0)2641 751 2105
peter.huebner@klinik-niederrhein.de

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers
05008

Study information

Scientific Title

Intermittent rehabilitation in the therapy of type 2 diabetes

Study objectives

An intermittent rehabilitation consisting of 3 weeks in-patient treatment, a follow up week after 6 months and frequent telephone calls leads to higher efficacy than standard rehabilitation.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Applied to the ethics committee of the Medical School Hanover, awaiting approval as of 10/08/06.

Study design

Randomised controlled trial with one intervention and one control group.

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Other

Study type(s)

Treatment

Participant information sheet**Health condition(s) or problem(s) studied**

Type two diabetes

Interventions

The intervention for both groups consists of a 3-week in-patient treatment. The goal is to improve diabetes specific knowledge and skills like balanced diet, physical exercise, foot care etc. Additionally the intervention group receives a follow-up week after 6 months to refresh the knowledge and gets expert advice every 6 weeks on the phone. This intensive care has the aim to remind and motivate the patients.

Intervention Type

Other

Phase

Not Specified

Primary outcome measure

1. Metabolic parameter HbA1c

Secondary outcome measures

1. Cardiovascular Risk-Score PROCAM
2. Body Mass Index (BMI)
3. Diabetes related quality of life and coping skills
4. Satisfaction with therapy
5. Diabetes related costs

The data will be collected in the beginning, after the rehabilitation and one year later.

Overall study start date

01/10/2006

Completion date

30/09/2009

Eligibility**Key inclusion criteria**

1. Covered by Deutsche Rentenversicherung (social pension fund)
2. Type 2 diabetes
3. Employable

Participant type(s)

Patient

Age group

Adult

Sex

Both

Target number of participants

420 patients

Total final enrolment

420

Key exclusion criteria

1. Inadequate knowledge of the German language
2. Inadequate writing and literacy
3. Phone calls are impossible
4. Follow-up is impossible
5. Serious secondary disease
6. Not employable in the next 12 months

Date of first enrolment

01/10/2006

Date of final enrolment

30/09/2009

Locations

Countries of recruitment

Germany

Study participating centre

Hochstrasse 13-19

Bad Neuenahr

Germany

53474

Sponsor information

Organisation

Refonet (Germany)

Sponsor details

Burgweg 3

Bad Neuenahr

Germany

53474

+49 (0)2641 90620

service@refonet.de

Sponsor type

Industry

Website

<http://www.refonet.de>

ROR

<https://ror.org/04yeh2x21>

Funder(s)

Funder type

Industry

Funder Name

Refonet - Rehabilitations-Forschungsnetzwerk der Deutschen Rentenversicherung Rheinland
(No. 05008) (Germany)

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/06/2009	06/01/2021	Yes	No